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Abstract
Although Inflammatory Breast Cancer (IBC) is a rare and an aggressive type of locally advanced breast cancer with a
generally worst prognosis, little work has been done in identifying the status of non-genomic signaling in the invasiveness
of IBC. The present study was performed to explore the status of non-genomic signaling as affected by various estrogenic
and anti-estrogenic agents in IBC cell lines SUM149 and SUM190. We have identified the presence of estrogen receptor a
(ERa) variant, ERa36 in SUM149 and SUM190 cells. This variant as well as ERb was present in a substantial concentration in
IBC cells. The treatment with estradiol (E2), anti-estrogenic agents 4-hydroxytamoxifen and ICI 182780, ERb specific ligand
DPN and GPR30 agonist G1 led to a rapid activation of p-ERK1/2, suggesting the involvement of ERa36, ERb and GPR30 in
the non-genomic signaling pathway in these cells. We also found a substantial increase in the cell migration and
invasiveness of SUM149 cells upon the treatment with these ligands. Both basal and ligand-induced migration and
invasiveness of SUM149 cells were drastically reduced in the presence of MEK inhibitor U0126, implicating that the
phosphorylation of ERK1/2 by MEK is involved in the observed motility and invasiveness of IBC cells. We also provide
evidence for the upregulation of p-ERK1/2 through immunostaining in IBC patient samples. These findings suggest a role of
non-genomic signaling through the activation of p-ERK1/2 in the hormonal dependence of IBC by a combination of
estrogen receptors. These findings only explain the failure of traditional anti-estrogen therapies in ER-positive IBC which
induces the non-genomic signaling, but also opens newer avenues for design of modified therapies targeting these
estrogen receptors.
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Introduction
Inflammatory Breast Cancer (IBC) is a rare and aggressive form
of locally advanced breast cancer affecting approximately 1–6% of
breast cancer patients in the United States [1]. It is reported by the
National Cancer Institute’s Surveillance, Epidemiology, and End
Results (SEER) that while the incidence of normal breast cancer
has been steadily decreasing, the incidence of IBC continues to be
increasing. SEER further reports that the overall survival rate of
IBC patients is significantly lower than non-IBC stage III breast
cancer [2]. The aggressive characteristic of IBC enables its
malignant cells to invade the dermal lymphatics of the breast,
causing the accumulation of fluids within lymphatic vessels and the
subsequent edematous red swelling of the breast [3]. By its ability
to metastasize rapidly, most IBC tumors are characterized as stage
IIIB at the time of detection [4]. These characteristics coupled
with the relatively poor prognosis makes IBC one of the most
deadly carcinomas.
Since the term IBC was coined by Lee and Tannebaum in
1924, there has been an extensive search for an effective way to
treat this disease. Although many groups have reported that the
prognosis of the disease can be improved by multimodality
treatment, improvement in the overall survival rate is still poor
due to the lack of a major molecular signature [5–7]. Several
studies have found that an alteration in the levels of molecules
such as RhoC, WISP-3 and Caveolin contribute significantly to
IBC progression, but an IBC-specific therapy still remains elusive
[8–11].
IBC is predominantly negative for estrogen receptor a (ERa)
and progesterone receptor (PR) and positive for human epidermal
growth factor receptor 2 (HER2) [12]. The absence of ERa makes
it difficult to treat IBC with traditional antiestrogens such as
tamoxifen. In addition to the wild-type ERa, several groups have
provided evidence for the existence of ERa splice variants. Of the
splice variants, ERa36 has been relatively well studied. ERa36 is
translated from a transcript initiated by a previously unidentified
promoter in the first intron of ERa gene and lacks both AF-1 and
AF-2 transactivation domains present in ERa [13]. ERa36 was
expressed in both ERa positive and negative breast carcinomas
and its expression was reduced with the presence of ERa [14].
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Furthermore, ERa36 has been shown to be capable of supporting
the non-genomic signaling pathways such as ERK and Akt in
endometrial carcinomas and HEK293 cells [15,16]. The search
for an alternate estrogen receptor led to an identification of a novel
G-protein coupled receptor, GPR30 that localized in the plasma
membrane, the cytoplasm and the endoplasmic reticulum [17–19].
GPR30 is responsible for its rapid activation of non-genomic
signaling pathway and is involved in the biological processes
including migration, proliferation, adhesion, gene regulation and
invasion of the cancer cells [18–21]. Interestingly, the classical
anti-estrogens such as tamoxifen and ICI 182780 are known to act
as agonists for ERa36 and GPR30. Therefore, these alternate
estrogen receptors are considered to contribute to the tamoxifen
resistance in a variety of tumors [22,23].
Stimulation of the estrogenic non-genomic signaling compo-
nents such as PI3K, Akt and ERK contributes to alterations in
the downstream effectors in a cell-type-specific manner and
causes rapid physiological responses in target tissues [24]. In
spite of the immense importance of non-genomic signaling
pathway in other tumors, little research has been done on its
role in IBC. In the present study, we discovered the presence of
ERa36 and ERb in IBC cells and also found an evidence for
the possible contribution of these variants in the stimulation of
p-ERK1/2 in response to treatment with agonists and
antagonists. Furthermore, we found that this stimulation of p-
ERK1/2 leaded to an enhanced migration and invasiveness of
IBC cells.
Results
Expression status of estrogen receptors in SUM149 and
SUM190 cells
The full-length ERa was negative in the IBC cell lines SUM149
and SUM190 (Fig. 1A), while ERa alternative splicing variant
ERa36 was substantially expressed in the both cell lines (Fig. 1A).
ERb was detectable in both SUM149 and SUM190 cells. As
expected, MDA-MB-231 and SKBR3 cells were positive and
negative for ERb expression, respectively. GPR30 were also
detected in both SUM149 and SUM190 as well as in GPR30-
positive cell lines MCF-7 and MDA-MB-468 (Fig.1A). Immuno-
flourescent labeling followed by visualization through scanning
confocal microscopy revealed that while ERa36 was predomi-
nantly localized in the cytoplasmic compartment in both SUM149
and SUM190 cells, ERb was detected with low expression levels in
the both cytoplasm and nucleus of these cell lines (Fig. 1B). GPR30
was present in both the cytoplasmic and nuclear compartment in
these cells.
Rapid activation of p-ERK1/2 by estrogen receptor
ligands in SUM149 and SUM190 cells
The localization of the estrogen receptors in the cytoplasmic
compartment presented a possibility of the involvement of non-
genomic signaling in these cells. To investigate this possibility,
SUM149 and SUM190 cells were treated with E2 (10 nM) after
maintained in 5% DCC medium for 48 hrs. We noticed a rapid
Figure 1. Estrogen receptor expression profiling in IBC cell lines SUM149 and SUM190. (A) Western blot analysis of ERa36, ERb and GPR30
(B) Immunofluorescent localization of ERa36, ERb and GPR30. Estrogen receptors (green) and DNA (blue) in these cells.
doi:10.1371/journal.pone.0030725.g001
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activation of p-ERK1/2 within 5 min of post E2 treatment in
SUM149 and SUM190 cells (Fig. 2A). However, the phosphor-
ylation of the other MAPKs JNK and p38 were hardly activated
by E2 treatment in SUM149 cells (supplementary Fig. S1). In
addition, Akt phosphorylation did not increased upon E2
treatment. Interestingly, we also found a rapid activation of p-
ERK1/2 in these cells upon treatment with 10 nM of ERb specific
ligand DPN and GPR30-specific agonist G1 (Fig. 2B, C).
However, there was no p-ERK1/2 activation upon the treatment
with 10 nM of ERa-specific ligand PPT (Fig. 2B).
The anti-estrogens 4OHT and ICI are known to inhibit the
response of E2 mediated by ERa. Next, we tested whether these
anti-estrogens could compromise the activation of p-ERK1/2 by
E2 treatment. Interestingly, we found that the treatment of IBC
cells with OHT or ICI, alone or in combination with E2
potentiated the magnitude of p-ERK1/2 stimulation by E2 (10
nM) or DPN (10 nM) (Fig. 3A). In addition, all of E2, 4OHT or
DPN at 1027 to 1029M activated p-ERK1/2 (Fig. 3B). Pretreat-
ment of SUM149 cells with a specific MEK inhibitor U0126
blocked the activation of p-ERK1/2 in response to stimulation
with E2, 4OHT, DPN or G1 in SUM149 cells (Fig. 4A). Confocal
microscopic analysis showed that E2 treatment induced cytoskel-
etal reorganization in SUM149 cells as revealed by actin staining
(Fig. 4B), indicating that the cell mobility might be positively
regulated by E2, which could be effectively blocked by the
pretreatment of MEK inhibitor U0126.
Figure 2. Estrogen receptor ligands induced ERK1/2 phosphorylation in SUM149 and SUM190 cells. (A–C) The cells were maintained in
5% DCC for 48 hours and then treated with E2 (10 nM), DPN (10 nM) or G1 (10 nM) for the indicated times and then ERK1/2 phosphorylation was
analyzed by western blotting. The expression level of total ERK was analyzed for normalization. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0030725.g002
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Activation of p-ERK1/2 promotes motility and
invasiveness of SUM149 cells
Downstream signaling through the activation of p-ERK1/2 has
been implicated in increasing the proliferation and motility in
numerous cancer cell models. Therefore, we initially investigated
whether E2 could stimulate IBC cell proliferation. The treatment
with E2 at different doses (0.1–10 nM) had no effect on the cell
proliferation (Supplementary Fig. S2). We then performed a
Boyden chamber migration and invasion assay. The results
showed that the treatment with E2 (10 nM) or/and 4OHT (100
nM) drastically increased the ability of the SUM149 cells to
migrate and invade into the lower side of the well through the
matrigel (Fig. 5A). To confirm if the observed increase in the
invasiveness of SUM149 cells is mediated by the ERK pathway,
we treated the cells with U0126 (20 mM) alone and in combination
with E2 (10 nM), and a substantial reduction in the migration and
invasion by inclusion of MEK inhibitor U0126 (Fig. 5B).
Activation of p-ERK1/2 in IBC tissues
To validate the proof-of-principle evidence of p-ERK1/2 in IBC
tumors, we examined immunohistochemically p-ERK1/2 expression
in the tissues from five IBC patients using anti-p-ERK1/2 antibody
(Fig. 6A). Three of five tissues displayed nuclear immunostaining of p-
ERK1/2 with strong (#1, #3) and the moderate (#2) intensity, and
two cases were negative or weak staining.
Discussion
ERa is known to be absent in many cases of IBC and its absence
is associated with poor clinical consequences [25–27]. In this
study, we did not detect ERa in both IBC cell line SUM149 and
SUM190, however, we identified the presence of ERa variant,
ERa36. ERa36 was found to be mainly present in plasma
membrane and cytoplasm and to be involved in estrogen non-
genomic signaling [15,28]. Subsequently, ERa36 has been
reported to be potentially involved in the non-genomic signaling
in several cancers including endometrial and gastric cancers
[16,29]. Recently, E2 treatment has been reported to enhance the
cell proliferation of ERa negative cell line, MDA-MB-231 and
MDA-MB-468 through EGFR/Src/ERK signaling pathway [30],
while the cell proliferation of SUM149 and SUM190 were not
affected by E2 treatment, indicating no stimulation of estrogen
mitogenic signaling. However, the migration and invasion were
promoted by E2 treatment in both SUM149 and SUM190 cells,
revealing that the non-genomic estrogen signaling might be
associated with the aggressive characteristic of IBC cells to invade
into lymph node.
The involvement of GPR30 in the non-genomic signaling is
found in both ER-positive and -negative breast cancer cells [18].
The activation of p-ERK1/2 by the treatment of GPR30-specific
agonist G1 also suggested the involvement of GPR30 in the non-
genomic signaling cascade in IBC cells. The fact that GPR30
Figure 3. Effect of traditional antiestrogen treatment in SUM149 and SUM190 cells. (A) Effect of 4-hyroxytamoxifen (4OHT) and ICI 182780
(ICI) on E2-induced ERK1/2 phosphorylation. The cells were maintained in 5% DCC for 48 hours and then pretreated with or without ICI (100 nM) or
4OHT (100 nM) for1 hour before the treatment with or without E2 (10 nM). ERK1/2 phosphorylation was analyzed by western blotting. (B) Effect of
dose dependent treatment of E2, 4OHT and DPN in SUM149 cells. The cells were maintained in 5% DCC for 48 hrs and then E2, 4OHT or DPN were
treated at three concentrations (1, 10, 100 nM) of for 5 min. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0030725.g003
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localized in the nucleus than in the cytoplasm in the IBC cells
might suggest its lower contribution in activating non-genomic
signaling by the GPR30 pathway. However, it has been shown
that the nuclear localized GPR30 could also participate in the
non-genomic signaling [31]. Kang et al. have shown that G1 is
also able to stimulate ERa36 [23]. Furthermore, they have shown
that the non-genomic signaling pathway through p-ERK1/2 is
directly mediated by ERa36 but not by GPR30, because the
activities of GPR30 promoted by estrogen were due to its ability
to induce ERa36 expression. However, it remains possible that
both receptors can play a crucial role in the non-genomic
signaling pathway. Although we did not investigate whether G1
treatment upregulated the expression of ERa36 in these cells,
there might be another layer of cross-talk between the GPR30
and ERa36 rather than the regulation of ERa36 protein
expression by GPR30 as the primary mechanism of the noted
non-genomic signaling.
In the IBC cells, the involvement of ERs in the non-genomic
signaling seems to be more complicated due to the expression of
ERb in addition to the expression of ERa36 and GPR30. The
involvement of ERb in the non-genomic signaling pathway has
been shown in several cancer cell lines [32,33]. The rapid
activation of p-ERK1/2 by treatment with ERb-specific ligand
DPN in IBC cells suggested a possible contribution of ERb in
the non-genomic signaling. Recent data from the uterine
carcinosarcoma suggests a possible combined role of ERb and
GPR30 in the non-genomic signaling [34]. In addition, co-
ordinated regulation of GPR30 and ERb in endometrial cells
upon E2 treatment also leads to an increased expression of
GPR30 mRNA through ERb [35]. Taken together, these data
provide us the possibility that all of GPR30, ERa36 and ERb
might be involved in the non-genomic signaling through a net-
work of cross-talks among ERs in IBC cells. However, further
studies must investigate these possibilities.
We also found that 4OHT and the pure antiestrogen ICI also
failed to block the E2-mediated activation of p-ERK1/2 in IBC
cells. The antiestrogens including tamoxifen, 4OHT and ICI
have been reported to act as agonists for ERa36 and GPR30 in a
variety of cancer cells [15,36–39]. One of potential mechanisms
which causes antiestrogen-resistant in some breast cancers could
be the stimulation of anti-estrogen signaling pathways via ERa36
[15]. Since expression of ER/PR is generally lower in IBC cells
[25,40,41], such agents are not used for IBC therapeutics. Our
findings presented here raise a new possibility that ERa variant
ERa36, ERb and GPR30 might be potentially targeted for IBC
therapeutic. In this context, a recent study has shown that estriol
could act as a GPR30 antagonist by inhibiting the GPR30-
mediated activation of p-ERK1/2 in ERa-negative breast cancer
cells [42]. Search and discovery for the other antiestrogens and
antagonists including estriol to block non-genomic signaling
components through ERs could provide novel insights into the
therapeutic strategy for IBC patients. In addition, we have
shown IBC non-genomic signaling function including the
migration and the invasiveness of SUM149 cells via estrogen-
and antiestrogen-mediated p-ERK1/2 activation (Figure 6B).
Our present study suggests that in addition to ERs-targeted
agents, the drugs which specifically inhibit ERK1/2 might prove
to be effective in IBC, either as a single agent or in combination
with targeted therapeutics to evolve an effective anti-IBC
therapeutic strategy.
Materials and Methods
Cell culture and reagents
SUM149 and SUM190 were obtained from Asterand, plc
(Detroit, MI) and maintained in Ham-F-12 (1:1) medium
supplemented with 5% Fetal Bovine Serum (FBS), 5 mg/ml
insulin, 1 mg/ml hydrocortisone and 10 mM HEPES. SUM149
cell line is obtained from the primary ductal carcinoma of the
breast from a patient with a locally advanced disease while
SUM190 is obtained from poorly differentiated inflammatory
breast carcinoma. Breast cancer cell lines MDA-MB-231, MDA-
MB-468 and MCF-7 were purchased from the American Type
Culture Collection (Manassas, VA) and maintained in maintained
in DMEM-F12 (1:1) supplemented with 10% FBS. Estradiol (E2)
and 4-hydroxytamoxifen (4OHT) were purchased from Sigma-
Aldrich (St. Louis, MO). The ERa-selective agonist propyl-
pyrazole-triol (PPT), ERb-selective agonist diarylpropionitrile
(DPN) and the ER antagonist ICI 182780 (ICI) were purchased
from TOCRIS (Ellisville, MO). The GPR30-specific agonist G1
was purchased from Merck KGaA (Darmstadt, Germany). MEK
inhibitor U0126 was obtained from Promega (Madison, WI). The
following antibodies were used: ERa (Bethyl Laboratories,
Montgomery, TX); ERb (Oncogene Research Products, San
Diego, CA); phospho-p42/p44 ERK/MAPK (Cell Signaling,
Beverly, MA); ERK1, ERK2, (Santa Cruz Biotechnology, Santa
Cruz, CA); GPR30 (MBL International,Woburn,MA); hERa36
antibody was kind gift from Dr. ZhanoYi Wang (Creighton
University Medical School, Omaha, NE).
Figure 4. Effect of MEK inhibitor U0126 on p-ERK1/2 activation
and cytoskeletal remodeling induced by estrogen receptor
ligands and antiestrogens. (A) Blocking of E2, DPN, 4OHT or G1
induced ERK1/2 phosphorylation in SUM149 cells by U0126. The cells
were maintained in 5% DCC for 48 hours and then pretreated with or
without U0126 (20 mM) for 15 min before treatment with or without E2
(10 nM), DPN (10 nM), 4OHT (10 nM) and G1 (10 nM) for 5 min. ERK1/2
phosphorylation was analyzed by western blotting. (B) Blocking of E2-
induced cytoskeletal change in SUM149 cells by U0126. The cells were
maintained for 48 hours in 5% DCC and then pretreated with U0126
(20 mM) before the treatment with or without E2 (10 nM) for 5 min. The
cells were fixed and labeled with fluorescently conjugated phalloidin
(for filamentous actin, red) and DAPI (for DNA). White-dotted areas in
upper panels were magnified in lower panels.
doi:10.1371/journal.pone.0030725.g004
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Cell extracts and immunoblotting
To prepare cell extracts, the cells were grown in 5% DCC
medium for the period of 48 hrs and then treated with either E2
(10 nM), DPN (10 nM), PPT (10 nM) or G1 (10 nM). When
indicated, ICI (1.0 mM) or 4OHT (1.0 mM) was added 1 hr before
and MEK inhibitor U0126 (20 mM) was added 15 min before
ligand treatment. The cells were washed once with PBS and then
lysed in radioimmunoprecipitation assay buffer [50 mmol/l Tris-
HCl (pH 7.5), 150 mmol/l NaCl, and 0.5% 16protease inhibitor
cocktail (Roche Applied Science, Indianapolis, IN)] for 10 minutes
on ice. The cell lysates were centrifuged at 13,000 rpm for 10 min
at 4uC. The cell lysates containing an equal amount of protein
were then resolved on a sodium dodecyl sulfate-polyacrylamide gel
(8% acrylamide), transferred to a nitrocellulose membrane, probed
with the appropriate antibodies, and developed using the ECL
detection reagent (Amersham Pharmacia Biosciences, Piscataway,
NJ).
Immunoflourescent labeling and confocal microscopy
The cellular localization of proteins was determined by indirect
immunofluorescence labeling. SUM149 and SUM190 cells were
grown on sterile glass coverslips in 5% DCC media for 48 hrs,
fixed in 4% paraformaldehyde, permeabilized in 0.1% Triton X-
100, and blocked in 5% normal goat serum-PBS. The cells were
incubated with the primary antibodies for 1 hr, washed thrice in
PBS, and then incubated with goat anti-mouse or goat anti-rabbit
Figure 5. E2-induced SUM149 cell migration and invasion. (A) For migration, the cells (2 6 104 cells) were added on the lower side of a
Boyden chamber and incubated for 14 hours. Then the cells that passed through the filters were fixed, stained, and counted (left). For invasion, the
cells (1 6 105 cells) were added to the lower side of a matrigel coated Boyden chamber and incubated for 20 hours. Then the cells that invaded
through the matrigel were fixed stained and counted (right). (B) The E2-induced migration and invasion was blocked by treatment with U0126. Error
bars indicate standard deviation.
doi:10.1371/journal.pone.0030725.g005
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secondary antibodies conjugated with Alexa 488 from Molecular
Probes (Eugene, OR). For actin cytoskeletal staining, phalloidin
conjugated with Alexa 546 was used (Molecular Probes). The
DNA dye DAPI was used as nuclear stain (blue).
Matrigel invasion and migration assays
To quantify the cell migration potential of IBC cells, the cells
were grown in 5% DCC media for 48 hrs. The cells were then
trypsinised for collection, washed in PBS, resuspended in 0% DCC
medium containing 0.1% BSA, and loaded into the upper well of
an uncoated Boyden chamber (BD Biosciences) at a concentration
of approximately 3.36104 cells/well. The lower side of the
separating filter was filled 0.2% DCC medium containing 0.1%
BSA. The cells were fixed after about 16 hrs and the cells which
had successfully migrated were stained and counted manually.
The same protocol was followed for measuring the invasion
potential with principal differences being the use of Matrigel-
coated Boyden chamber (BD Biosciences) and loading of 16105
cells/well.
Immunohistochemistry
Deparaffinized sections were subjected to antigen retrieval by
boiling the sections in 10 mM citric acid buffer (pH 6.0) for
10 min. Sections were then incubated with rabbit p-ERK1/2
antibody (Cell Signaling) at 4uC overnight, followed by incubation
with EnVision (Dako, Carpinteria, CA) for 1 hour at room
temperature. Immunostained sections were lightly counterstained
with hematoxylin, dehydrated in graded ethanol, cleared in
xylene, and mounted with the use of the peramount mounting
medium.
Supporting Information
Figure S1 Phosphorylation of Akt, JNK and p38 upon E2
treatment in SUM149 cells. The cells were maintained in 5%
DCC for 48 hours and then treated with E2 (10 nM) and then Akt,
JNK and p38 phosphorylation were analyzed by western blotting.
(TIF)
Figure S2 Cell proliferation of SUM149 with E2 treat-
ment. The cells were plated in 6-well plates and treated with E2
the next day. The cell growth was determined by counting cell
number using a Coulter Counter.
(TIF)
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